Результаты поиска

Osteoporosis prevention clinical study program.

OBJECTIVES: Oestrogens are widely believed to be effective against postmenopausal osteoporosis. However there are some outstanding questions … y in study 305, (the two studies are otherwise identical). All 'active-dose' treated groups receive dydrogesterone 20 mg/day during the last 14 days of Menorest administration and placebo tablets are given to the placebo patch group. The main entry criteria are natural or surgical menopause, (with hormonal confirmation) from 1 to 6 years, with no contra-indicati …

Hormone replacement therapy in women with cancer and risk of cancer-specific mortality and cardiovascular disease: a protocol for a cohort study from Scotland and Wales.

BackgroundHormone replacement therapy (HRT) is widely used and has proven benefits for women with menopausal symptoms. An increasing number of women with cancer experience menopausal symptoms but the safety of HRT use in women with cancer is unclear. There are particular concerns that HRT could accelerate cancer progression in women with cancer, and also that HRT could increase the risk of cardiovascular disease in such women. Therefore, our primary aim is to determine whether HRT use alters the risk of cancer-specific mortality in women with a range of common cancers. Our secondary objectives

Совпадение в полном тексте источника
… We will capture both the route of administration (oral, transdermal, vaginal, injection or implant) and type of HRT including oestrogen-only (conjugated equine oestrogen and estradiol) and combined oestrogen with progestogen preparations (oestrogen with medroxyprogesterone acetate, dydrogesterone, norethisterone …

Effect of vaginal estrogen supplementation for luteal phase support in the GnRH antagonist protocol on pregnancy outcomes for IVF/ICSI cycles: a randomized controlled trial.

STUDY QUESTION: Does adding vaginal estradiol to standard progesterone luteal phase support improve ongoing pregnancy rates in normal-respon … l support initiated on Day 1 post-oocyte retrieval comprised: vaginal progesterone 90 mg/day + oral dydrogesterone 10 mg twice daily for both groups, with the E + P group additionally receiving vaginal 17β-estradiol 2 mg nightly. The primary outcome was ongoing pregnancy rate, with secondary outcomes including the rates of implantation, clinical pregnancy, live …

Cervical stitch (cerclage) in combination with other treatments for preventing spontaneous preterm birth in singleton pregnancies.

BACKGROUND: Preterm birth (PTB) remains the foremost global cause of perinatal morbidity and mortality. Thus, the prevention of spontaneous … essary, reinforcing or second cervical cerclage placement, 17-alpha-hydroxyprogesterone caproate or dydrogesterone or vaginal micronised progesterone, omega-3 long chain polyunsaturated fatty acid supplementation and bed rest.

Clinical Practice Guidelines for Menopause: An Executive Summary and Recommendations: Indian Menopause Society 2026.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.